KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer.

Nilofer S Azad, Z Ian Hu, Priyadarshini Pathak, Ilyas Sahin, Olivia Aranha, Renuka Iyer, Gregory M Heestand, Chih-Yi Liao, Howard S Hochster, Aparna Kalyan, Anthony El-Khoueiry, Andrew Scott Paulson, Robin Kate Kelley, Mitesh J Borad, Lipika Goyal, Cynthia A Sirard, Thomas J Schuetz, Milind Javle

J Clin Oncol JCO2602188

PMID42920414
PMCID-
DOI10.1200/JCO-26-02188
发表日期2026-10-24
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

PURPOSE: Patients with previously treated biliary tract cancer (BTC) have a short median overall survival (OS) and few treatment options. Tovecimig, a bispecific antibody to delta-like ligand-4 and vascular endothelial growth factor (VEGF)-A, was evaluated in combination with paclitaxel in COMPANION-002, a randomized phase II/III study in pretreated patients with advanced BTC. PATIENTS AND METHODS: Patients with advanced BTC with one prior systemic therapy were randomly assigned to paclitaxel (80 mg/m2; once weekly on days 1, 8 and 15) with or without tovecimig (10 mg/kg; once every 2 weeks on days 1 and 15) in each 28-day cycle. The primary end point was RECIST v1.1-defined overall response rate (ORR) as assessed by blinded independent central review (BICR). Secondary end points included progression-free survival (PFS) and OS. Crossover from the paclitaxel control arm to tovecimig plus paclitaxel was permitted following BICR-confirmed progression. RESULTS: A total of 168 patients were randomly assigned 2:1 to tovecimig + paclitaxel (n = 111) or paclitaxel alone (n = 57). Tovecimig + paclitaxel significantly improved BICR-assessed ORR (18.0% v 5.3%; P = .0228) and PFS (4.7 v 2.6 months; hazard ratio [HR], 0.44; P < .0001). Among 31 patients (54%) who crossed over, postprogression PFS (time from crossover to subsequent second progression) exceeded initial PFS (PFS from random assignment to initial progression on paclitaxel; 3.5 v 1.9 months; HR, 0.40; P = .0035). Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P = .779). The most common treatment-emergent adverse events (TEAEs) with tovecimig + paclitaxel were hypertension (69.4%) and fatigue (66.7%). Grade ≥3 TEAEs occurred in 93.5% and 64.2% of patients treated with tovecimig + paclitaxel and paclitaxel alone, respectively. CONCLUSION: Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。